Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27519797 | 0.80 | PKM (0.58) | ALDH1A1SMN1; SMN2LMNAHTTTSHR | |
| SCHEMBL11536910 | 0.78 | ALDH1A1 (1.00) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2981180 | 0.77 | ALDH1A1 (0.97) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL26313603 | 0.77 | ALDH1A1 (0.97) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3316800 | 0.75 | CYP2C9 (0.50) | ALDH1A1LMNATSHRL3MBTL1 | |
| SCHEMBL3317094 | 0.75 | PKM (0.57) | ALDH1A1SMN1; SMN2LMNAHTTTSHR | |
| SCHEMBL5560091 | 0.72 | LMNA (1.00) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5915288 | 0.71 | L3MBTL1 (0.54) | ALDH1A1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL334552 | 0.71 | ALDH1A1 (0.73) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3847472 | 0.71 | ALDH1A1 (0.97) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | BIOGEN, INC. | 2004-07-08 | — | — | US | claimed |
| US-6630503-B1 | Non-peptidic sulfonamide compounds that specifically inhibit the binding of ligands to VLA-4 for inhibition, prevention and suppression of VLA-4-mediated cell adhesion and pathologies such as inflammation and immune reactions | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | VCAM1, ICAM1, EPCAM | ALDH1A1 631/4885NPC1 2287/4885MAPT 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.